-
公开(公告)号：US20230330201A1
公开(公告)日：2023-10-19
申请号：US18309555
申请日：2023-04-28
Applicant: UNIVERSIDAD DE ZARAGOZA , BIOFABRI S.L.
Inventor： Carlos MARTÍN MONTAÑES , Juan Ignacio AGUILÓ ANENTO , Jesús Ángel GONZALO ASENSIO , Dessislava Vaneva MARINOVA , Santiago UGANDA MAÍZ , Esteban RODRÍGUEZ SÁNCHEZ , Eugenia PUENTES COLORADO , Concepción FERNÁNDEZ ÁLVAREZ-SANTULLANO
CPC classification number: A61K39/04 , A61P37/04 , C12N1/20 , A61K2039/522
Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberucolosis complex, preferably a M. tuberculos clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype) (the MTBVAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberulosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.
-
公开(公告)号：US20230165948A1
公开(公告)日：2023-06-01
申请号：US16971248
申请日：2019-02-19
Applicant: UNIVERSIDAD DE ZARAGOZA , BIOFABRI S.L.
Inventor： Carlos MARTÍN MONTAÑES , Juan Ignacio AGUILÓ ANENTO , Jesús Ángel GONZALO ASENSIO , Dessislava Vaneva MARINOVA , Santiago UGANDA MAÍZ , Esteban RODRÍGUEZ SÁNCHEZ , Eugenia PUENTES COLORADO , Concepción FERNÁNDEZ ÁLVAREZ-SANTULLANO
CPC classification number: A61K39/04 , C12N1/20 , A61P37/04 , C12N2500/32 , A61K2039/522
Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberculosis complex, preferably a M. tuberculosis clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype) (the MTB VAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberculosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.
-
公开(公告)号：US20240382575A1
公开(公告)日：2024-11-21
申请号：US18788724
申请日：2024-07-30
Applicant: UNIVERSIDAD DE ZARAGOZA , BIOFABRI S.L.
Inventor： Carlos MARTÍN MONTAÑES , Juan Ignacio AGUILÓ ANENTO , Jesús Ángel GONZALO ASENSIO , Dessislava Vaneva MARINOVA , Santiago UGANDA MAÍZ , Esteban RODRÍGUEZ SÁNCHEZ , Eugenia PUENTES COLORADO , Concepción FERNÁNDEZ ÁLVAREZ-SANTULLANO
Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberucolosis complex, preferably a M. tuberculos clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype) (the MTBVAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberulosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.
